Goldman Sachs Maintains Neutral on Ultragenyx Pharmaceutical, Lowers Price Target to $19

Benzinga Newsdesk www.benzinga.com Negative 65.4%

Neg 65.4% Neu 0% Pos 0%

Goldman Sachs analyst Salveen Richter maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Neutral and lowers the price target from $28 to $19.